Artrya (AYA) is held by 9 ASX ETFs. Over the last 3 months it fell 48.2%: on $10,000, −$4817. We explain 4 big moves in that time.
About AYA
- SectorHealth Care
- IndustryHealth Care Equipment & Services
- Size$560.6m
- Held by9 ETFs
- Big moves4 in 3M
Each dot is a move we explain. Tap one, or a row of Why it moved, to see what caused it.
Why it moved
- +9.3%2 Oct 2026· Contract
Artrya signed a five-year commercial agreement with Huntsville Hospital Health System for its Salix AI cardiac imaging product, driving a ~9% share price gain.
- +8.2%18 Sep 2026· Operational
Artrya's shares surged on exceptionally high volume likely driven by growing investor interest in its AI cardiac imaging commercialisation progress, amplified by multiple media mentions and analyst coverage in the days prior.
- −16.7%10 Sep 2026· Stake Change
A substantial holder (Regal Partners) reduced its stake in Artrya to 9.97%, triggering a sharp sell-off as the market interpreted the institutional exit as a negative signal.
- −16.4%30 Jul 2026· Operational
A quarterly activity report or operational update released around 29 July 2026 disappointed investors, causing the stock to sell off sharply despite no broader sector weakness driving the move.
Held by 9 ETFs
Of every $10,000 in each fund, how much is in AYA today.
- XMETBetaShares Energy Transition Metals ETF$3693.69%
- SLVMGlobal X Silver Miners ETF$2312.31%
- MNRSBetaShares Global Gold Miners Currency Hedged ETF$660.66%
- ATECBETASHARES S&P/ASX AUSTRALIAN TECHNOLOGY ETF$470.47%
- GDXVanEck Gold Miners ETF$400.40%
- SSOSTATE STREET SPDR S&P/ASX SMALL ORDINARIES ETF$180.18%
- ISOiShares S&P/ASX Small Ordinaries ETF$180.18%
- VISMVanguard MSCI International Small Companies Index ETF$3.520.04%
- VASVanguard Australian Shares Index ETF$1.380.01%
Why did AYA fall 16.4% on 30 Jul 2026?
Artrya
A quarterly activity report or operational update released around 29 July 2026 disappointed investors, causing the stock to sell off sharply despite no broader sector weakness driving the move.
The Kalkine headline from 29 July explicitly notes that Artrya 'declines despite sector strength,' confirming the move is company-specific rather than sector-driven — the health sector index only fell 0.81%, well below AYA's 16.35% drop. The Stockhead 'biotech quarterlies' article published at the same time suggests a quarterly activity report was the likely catalyst, consistent with ASX small-cap biotech reporting cycles. No formal ASX announcement was captured in Layer 1, but the news articles point strongly to a company-specific negative development around that date, most probably a disappointing quarterly update.
General information only, not personal advice — prepared without regard to your objectives, financial situation or needs. Past performance is not indicative of future performance.
Evidence
News coverage
Sector / macro signals
What it did to the 9 ETFs holding AYA
On $10,000 in each fund, at the weight it holds today